2-(Boc-氨基)-4-(氨甲基)吡啶 | 639091-78-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-(Boc-氨基)-4-(氨甲基)吡啶
• 中文别名: (4-氨基甲基吡啶-2-基)氨基甲酸叔丁酯；2-(BOC-氨基)-4-(氨甲基)吡啶
• 英文名称: tert-butyl (4-(aminomethyl)pyridin-2-yl)carbamate
• 英文别名: tert-butyl N-[4-(aminomethyl)pyridin-2-yl]carbamate
• CAS: 639091-78-4
• 化学式: C₁₁H₁₇N₃O₂
• 分子量: 223.275
• InChiKey: MTLPTFRZCYSDNT-UHFFFAOYSA-N

物化性质

• 熔点：
  131-132 °C
• 沸点：
  321.9±32.0 °C(Predicted)
• 密度：
  1.164±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  77.2
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(Boc-amino)-4-(aminomethyl)pyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(Boc-amino)-4-(aminomethyl)pyridine
CAS number: 639091-78-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H17N3O2
Molecular weight: 223.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(Boc-氨基)-4-(氨甲基)吡啶 在 盐酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 N-[(2-aminopyridin-4-yl)methyl]-6-[4-[[3-(trifluoromethyl)phenyl]methoxy]phenoxy]pyridine-3-carboxamide
  参考文献：
  名称：

  Discovery of an N-(2-aminopyridin-4-ylmethyl)nicotinamide derivative: a potent and orally bioavailable NCX inhibitor

  摘要：

  Ca2+ overload in myocardial cells is responsible for arrhythmia. Sodium-calcium exchanger (NCX) inhibitors are more effective than sodium hydrogen exchanger (NHE) inhibitors with regard to modulation of Ca2+ overload, because NCX inhibitors can directly inhibit the influx of Ca2+ into cells. NCX is an attractive target for the treatment of heart failure and ischemia-reper-fusion. We have designed and synthesized a series of N-(2-aminopyridin-4-ylmethyl)nicotinamide derivatives, based on compound 5. We have discovered a novel NCX inhibitor (23h) with an IC50 value of 0.12 mu M against reverse NCX. The inhibitory activities of our NCX inhibitors against cytochrome P450 were also evaluated. The effects on heart failure and the pharmacokinetic profile of compound 23h are discussed. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.03.052
• 作为产物：
  描述：

  2-氯异烟酸 在 sodium tetrahydroborate 、 硫酸 、 氨 、 一水合肼 、 三乙胺 、 calcium chloride 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 氯仿 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 87.0h， 生成 2-(Boc-氨基)-4-(氨甲基)吡啶
  参考文献：
  名称：

  Discovery of an N-(2-aminopyridin-4-ylmethyl)nicotinamide derivative: a potent and orally bioavailable NCX inhibitor

  摘要：

  Ca2+ overload in myocardial cells is responsible for arrhythmia. Sodium-calcium exchanger (NCX) inhibitors are more effective than sodium hydrogen exchanger (NHE) inhibitors with regard to modulation of Ca2+ overload, because NCX inhibitors can directly inhibit the influx of Ca2+ into cells. NCX is an attractive target for the treatment of heart failure and ischemia-reper-fusion. We have designed and synthesized a series of N-(2-aminopyridin-4-ylmethyl)nicotinamide derivatives, based on compound 5. We have discovered a novel NCX inhibitor (23h) with an IC50 value of 0.12 mu M against reverse NCX. The inhibitory activities of our NCX inhibitors against cytochrome P450 were also evaluated. The effects on heart failure and the pharmacokinetic profile of compound 23h are discussed. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.03.052

文献信息

• Structure-activity relationship investigation of Phe-Arg mimetic region of human glutaminyl cyclase inhibitors
  作者：Van T.H. Ngo、Van-Hai Hoang、Phuong-Thao Tran、Nguyen Van Manh、Jihyae Ann、Eunhye Kim、Minghua Cui、Sun Choi、Jiyoun Lee、Hee Kim、Hee-Jin Ha、Kwanghyun Choi、Young-Ho Kim、Jeewoo Lee

  DOI：10.1016/j.bmc.2018.04.040

  日期：2018.7

  AβN3pE-40-lowering effects in in vivo acute model with reasonable BBB penetration, without showing cytotoxicity and hERG inhibition. The molecular modeling analysis of 53 indicated that the salt bridge interaction and the hydrogen bonding in the active site provided a high potency. Given the potent activity and favorable BBB penetration with low cytotoxicity, we believe that compound 53 may serve as a

  谷氨酰环化酶（QC）由于其参与了阿尔茨海默氏病的发病机理，因此是有希望的治疗靶标。在这项研究中，我们开发了新型的QC抑制剂，其中包含3-氨基烷氧基-4-甲氧基苯基和4-氨基烷氧基苯基，以取代先前开发的药效团。鉴定了几种有效的抑制剂，显示出低纳摩尔范围的IC50值，并进一步研究了其体外毒性和体内活性。其中，抑制剂51和53在具有合理的BBB渗透的体内急性模型中显示出最有效的AβN3pE-40降低作用，而没有细胞毒性和hERG抑制作用。53的分子模型分析表明，活性位点中的盐桥相互作用和氢键提供了高效力。
• Structure-Based Design, Synthesis, and A-Site rRNA Cocrystal Complexes of Functionally Novel Aminoglycoside Antibiotics:  C2‘ ‘ Ether Analogues of Paromomycin
  作者：Stephen Hanessian、Janek Szychowski、Susanta Sekhar Adhikari、Guillermo Vasquez、Pachamuthu Kandasamy、Eric E. Swayze、Michael T. Migawa、Ray Ranken、Boris François、Julia Wirmer-Bartoschek、Jiro Kondo、Eric Westhof

  DOI：10.1021/jm061200+

  日期：2007.5.1

  A series of 2"-O-substituted ether analogues of paromomycin were prepared based on new site-selective functionalizations. X-ray cocrystal complexes of several such analogues revealed a new mode of binding in the A-site rRNA, whereby rings I and II adopted the familiar orientation and position previously observed with paromomycin, but rings III and IV were oriented differently. With few exceptions,

  根据新的位点选择性功能化，制备了一系列2'-O-取代的巴龙霉素醚类似物。几种类似物的X射线共晶复合物揭示了在A位rRNA中的新结合方式，即环I和II采用了以前对巴龙霉素观察到的熟悉的方向和位置，但环III和IV的取向不同，除少数例外，所有这些新类似物对敏感的金黄色葡萄球菌均表现出与巴龙霉素相同或更好的抑制活性。获得了针对大肠杆菌的MIC值，其中一些醚附件含有极性或碱性端基；两种类似物在小鼠败血病保护试验中显示出优异的存活率；对肾脏的初步组织病理学分析未显示明显的毒性迹象，而使用新霉素和卡那霉素的对照组在较低剂量下有毒。
• [EN] NEW 5,6-DIHYDROPYRIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN<br/>[FR] NOUVEAUX COMPOSES DE 5,6-DIHYDROPYRIN-2-ONE UTILES EN TANT QU'INHIBITEURS DE THROMBINE
  申请人：ASTRAZENECA AB

  公开号：WO2005058826A1

  公开（公告）日：2005-06-30

  There is provided a compound of formula (I) wherein R1, R2a, R2b, R3a, R3b, R4, R5, R6, A, G and L have meanings given in the description, which compounds are useful as, or are useful as prodrugs of, competetive inhibitors of trypsin-like proteases, such as trombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is beneficial (e,g. conditions, such as thrombo-embolisms, where inhibition of trombin is required or desired, and/or conditions wherea anticoagulant thererapy is indicated).

  提供了一个式(I)的化合物，其中R1、R2a、R2b、R3a、R3b、R4、R5、R6、A、G和L的含义如描述中所给，这些化合物可用作或可用作胰蛋白酶类竞争性抑制剂的前体药物，例如血栓素，因此特别适用于治疗需要抑制血栓素有益的疾病（例如需要或希望抑制血栓素的血栓栓塞等疾病，以及抗凝治疗适用的疾病）。
• [EN] NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN<br/>[FR] NOUVEAUX COMPOSES DE PYRIDIN-2-ONE UTILISABLES EN TANT QU'INHIBITEURS DE THROMBINE
  申请人：ASTRAZENECA AB

  公开号：WO2005075424A1

  公开（公告）日：2005-08-18

  There is provided a compound of formula I, wherein the dashed line, R1, R2, R3a, R3b, A, D, E, G and L have meanings given in the description, which compounds are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is beneficial (e.g. conditions, such as thrombo-embolisms, where inhibition of thrombin is required or desired, and/or conditions where anticoagulant therapy is indicated).

  提供了一个式I的化合物，其中虚线、R1、R2、R3a、R3b、A、D、E、G和L的含义如描述中所示，这些化合物可用作竞争性蛋白酶抑制剂，如凝血酶，或者可用作其前药，特别适用于需要抑制凝血酶有益的情况的治疗（例如需要或希望抑制凝血酶的情况，如血栓栓塞等情况，以及需要抗凝治疗的情况）。
• Protein-Induced Change in Ligand Protonation during Trypsin and Thrombin Binding: Hint on Differences in Selectivity Determinants of Both Proteins?
  作者：Khang Ngo、Chelsey Collins-Kautz、Stefan Gerstenecker、Björn Wagner、Andreas Heine、Gerhard Klebe

  DOI：10.1021/acs.jmedchem.9b02061

  日期：2020.3.26

  (ITC), we studied a series of d-Phe/d-DiPhe-Pro-(amino)pyridines. Identical ligand pairs show the same binding poses. Surprisingly, one ligand binds to trypsin in protonated state and to thrombin in unprotonated state at P1 along with differences in the residual solvation pattern. While trypsin binding is mediated by an ordered water molecule, in thrombin, water is scattered over three hydration sites

  胰蛋白酶和凝血酶是结构相似的丝氨酸蛋白酶，可识别不同的底物。凝血酶在Arg后裂解，而胰蛋白酶在Lys / Arg后裂解。两者都通过S1口袋底部的Asp189识别基本的基板头基。通过晶体学和等温滴定热法（ITC），我们研究了一系列d -Phe / d-DiPhe-Pro-（氨基）吡啶。相同的配体对显示相同的结合姿势。出人意料的是，一种配体在P1处以质子化状态的胰蛋白酶和未质子化状态的凝血酶结合，并残留溶剂化方式不同。虽然胰蛋白酶结合是由有序的水分子介导的，但在凝血酶中，水却分散在三个水合位点上。尽管具有高度相似的S1口袋，我们的结果表明Asp189的不同静电性质可能有助于选择性的决定因素。凝血酶与胰蛋白酶中不存在的Asp189旁的特定Na +离子结合。凝血酶中S1边缘的带电Glu192进一步削弱了整个S1袋的静电特性，而胰蛋白酶中的不带电Gln192代替了该电荷。